Brazilian pediatric doctor Monica Levi, one of the volunteers who received the COVID-19 vaccine, works at the Specialized Clinic in Infectious and Parasitic Diseases and Immunizations (CEDIPI), in Sao Paulo, Brazil, on July 24, 2020. - The doctor is one of the 5,000 volunteers participating in Brazil of the phase 3 trials - the last before homologation - of the ChAdOx1 nCoV-19 vaccine, developed by the University of Oxford together with the British pharmaceutical company AstraZeneca. (Photo by NELSON ALMEIDA / AFP) (Photo by NELSON ALMEIDA/AFP via Getty Images)
A volunteer participating in phase three trials in Brazil (Picture: AFP via Getty)

The coronavirus vaccine being developed at Oxford University is working well and has been shown to produce a ‘strong immune response’ in volunteers, studies show.

Instead of using a weakened strain, or small parts of it, like traditional vaccines, the Oxford jab directs the body to produce part of the virus itself.

Researchers led by the University of Bristol found it effectively delivers genetic instructions telling the body how to make the spike protein from SARS-CoV-2, the virus that causes Covid-19.

Once the protein is replicated, the immune system then reacts to it – training the body recognise the disease and be able to fight it off without the person falling ill.

Dr David Matthews, from Bristol’s School of Cellular and Molecular Medicine (CMM), led the research.

He said: ‘This is an important study as we are able to confirm that the genetic instructions underpinning this vaccine, which is being developed as fast as safely possible, are correctly followed when they get into a human cell.

‘Until now, the technology hasn’t been able to provide answers with such clarity, but we now know the vaccine is doing everything we expected and that is only good news in our fight against the illness.’

OXFORD, ENGLAND - JUNE 24: A scientist at work during a visit by Prince William, The Duke of Cambridge to the manufacturing laboratory where a vaccine against COVID-19 has been produced at the Oxford Vaccine Group's facility at the Churchill Hospital on June 24, 2020 in Oxford, England. Trials began on 23rd April, with ten thousand people across the UK in the process of being vaccinated in the latest study to assess the potential success of the treatment, with the UK Government providing ??84 million for the University of Oxford to develop and manufacture its coronavirus vaccine. (Photo by Steve Parsons - WPA Pool/Getty Images)
A scientist at work at the Oxford Vaccine Group’s facility at the Churchill Hospital (Picture: Getty)

Sarah Gilbert, who leads the Oxford University vaccine trial, added: ‘The study confirms that large amounts of the coronavirus spike protein are produced with great accuracy, and this goes a long way to explaining the success of the vaccine in inducing a strong immune response.’

The positive development comes after the government’s chief scientific adviser warned that a widespread roll-out of a coronavirus vaccine is unlikely before Christmas.

Sir Patrick Vallance told a Downing Street press briefing this week that ‘things are progressing well’ with vaccines ‘that produce an immune response’ in phase three clinical trials.

But he added: ‘I remain of the view that the possibility of wider-spread use of vaccines isn’t going to be until spring or so next year, by the time we get enough doses and enough understanding of the outputs to use them.’

Chief scientific adviser Sir Patrick Vallance during a media briefing in Downing Street, London, on coronavirus (COVID-19). PA Photo. Picture date: Thursday October 22, 2020. See PA story HEALTH Coronavirus. Photo credit should read: Henry Nicholls/PA Wire
Chief scientific adviser Sir Patrick Vallance during a media briefing in Downing Street (Picture: PA)

Sir Patrick said ‘the aim that we would all wish for’ would be a vaccine which would allow the ‘release’ of lockdown measures such as social distancing and the compulsory wearing of masks.

He later told a meeting of the Lords’ National Security Strategy Committee he believes it is ‘unlikely’ we will end up with a vaccine ‘that completely stops infection’, with the more likely scenario being ‘that the disease will circulate and be endemic’.

Sir Patrick went on: ‘Clearly, as management becomes better, as you get vaccination which will decrease the chance of infection and the severity of disease, or whatever the profile of the vaccines are, this then starts to look more like annual flu than anything else.

‘That may be the direction we end up going in.’

Get in touch with our news team by emailing us at webnews@metro.co.uk.

For more stories like this, check our news page.